Diabetes insipidus occurs as a result of vasopressin deficiency (antidiuretic hormone caused by a hypothalamic-pituitary disorder, which is known as central diabetes insipidus) or by resistance of the kidneys to vasopressin (nephrogenic diabetes insipidus). The disease is primarily characterized by polyuria (abundant urine excretion) and polydipsia (pathological need to drink water) and is confirmed by...
Introduction Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus, leading to significant morbidity and an increased risk of lower limb amputations. The management of DFUs presents a substantial challenge in healthcare, necessitating innovative treatments to enhance healing and reduce amputation rates. One such advancement is Heberprot-P, a novel therapeutic approach developed to...
For Diabetic Foot Ulcer, Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in 2007 in Cuba. Diabetes is no longer considered life threatening, nonetheless diabetes and complications due to diabetes, when not under control, remain to be sixth leading cause of death having a higher mortality rate than some...